Danimer Scientific reported Q2 2024 revenues of $7.6 million, down from $12.9 million in Q2 2023, primarily due to the reapportionment of Starbucks' straw business and a loss of PLA orders from customers affected by the conflict in Ukraine. The company is forecasting annualized PHA revenues to more than triple by the end of Q2 2025 and has retired $6.1 million of convertible notes.
Revenues for Q2 2024 were $7.6 million, a decrease of $5.3 million compared to Q2 2023.
PHA revenue decreased by $2.5 million year-over-year, mainly due to Starbucks' straw business changes.
PLA revenue decreased by $2.4 million due to lost orders from customers affected by the conflict in Ukraine.
The company completed a pro-rata warrant dividend transaction, retiring $6.1 million of convertible notes.
The company has adjusted its full-year Adjusted EBITDA guidance to a range of $(30) million to $(35) million and expects year-end liquidity to be in the range of $15 million to $20 million. They forecast annualized PHA revenues to more than triple by the end of the second quarter of 2025.
Visualization of income flow from segment revenue to net income